Category: Press Releases

VistaJet’s Global 7500

Conservation, relaxation and immersion to keep exploring the world throughout the year

London, December 14, 2021: VistaJet, the first and only global business aviation company, announces its new 2022 shortlist of inspired journeys, exclusive escapes and preferred partners around the world.

As privacy and safety continue to be vital for global travelers, the demand for private flights continues on an upward trajectory — VistaJet organized over 9,000 flights in Q3 2021, an increase of 35% against last year and up 19% on pre-pandemic figures. And as clients prefer to travel with more of their friends and extended families, passenger numbers are also registering a 23% surge.

The changes in private travel habits do not stop here. VistaJet Members are requesting longer trips to reach destinations further afield across the globe, many of them choosing to embark on big adventures and far-flung expeditions — on a quest for new, thrilling and memorable moments. Recent incredible non-stop journeys include St Maarten to the Seychelles (14 hours 45 minutes flight time), Honolulu to Helsinki (13 hours 30 minutes flight time) and Liège to Jakarta (13 hours 30 minutes flight time). All made possible by VistaJet’s fleet of six brand new Global 7500 jets — with a range of 7,700 nautical miles, it is the largest, fastest and longest-range aircraft in business aviation, opening up a new world of long-haul private flying.

Continuing its partnership with a network of world-leading travel experts and properties, including PELORUS, Kisawa, EYOS, GUEST, Wilderness Safaris and Based On A True Story, VistaJet’s Private World grants its Members exclusive access with the simplest door-to-door service and a host of personal services to create unforgettable moments — the ultimate notion of private travel.

To inspire taking off for the most incredible life adventures in 2022, VistaJet’s collection of Private World recommendations include:

A family treasure hunt by submarine — the Bahamas
with PELORUS
Dive to the depths of the Great Bahama Bank — an idyllic area of the Caribbean more than 65 million years old, characterized by its stunning coral reefs and marine life. VistaJet Members can get up close and partake in conservation efforts, researching sharks, whales and other marine life as they explore aboard a submarine. Younger guests can race to find pirate treasures in this fun and educational adventure, offering an exclusive and never-before-seen experience that will appeal to all the family. An archipelago of nearly 700 beautiful islands, the Bahamas is an exotic location of palm-fringed white sandy beaches bordered by vibrant aquamarine water. Embark on a family-friendly odyssey aboard a classic sailing yacht, offering a mix of comfortable luxury and the chance to stay right in the heart of all the action.

Conservation and exploring the Altai — Mongolia
with Based On A True Story
Explore this extreme, nomadic and bewildering Mongolia, traveling through its wide expanses of untouched rolling hills, the striking Lake Khövsgöl and the Tsaatan reindeer herders. Discover the remarkable landscapes, spending nights with nomads sleeping in traditional ger tents, redesigned to include all the modern luxuries. VistaJet Members are welcomed to the majestic, glaciated Altai Mountains, home to the iconic Kazakh eagle hunters, getting to know their hosts, riding on horseback with them as they hunt, learning how the young birds are trained, watching games such as ‘kukhbar’, and getting an incredible first-hand insight into this vanishing way of life.
Next, they can work with local researchers and conservationists to track the rare and endangered Mongolian snow leopard — assisting field experts in setting up camera traps, tagging satellite tracking collars and learning how local communities and conservationists are working together to safeguard these precious cats.
Other highlights include traditional music with an impromptu ‘dombra’ concert by local musicians; a Naadam festival and Mongolian archery; climbing to the top of the Khongoryn Els dunes in the Gobi Desert; and a camel ride to the Flaming Cliffs of Bayanzag, the world’s largest dinosaur graveyard.

The land of superlatives — Greenland
with EYOS
The earth’s largest island is also the least densely populated country and contains the world’s largest and most northernly national park. The longest fjord in the world is East Greenland’s Scoresby Sund (Kangertittivaq), a dendritic labyrinth of wilderness over 200 miles long.
Close to ninety percent of Greenlanders are ethnically Inuit, which is the highest proportion by far in any of the Arctic countries.
VistaJet Members can embark on this incredible journey of discovery by expedition yacht, aboard the Nansen Explorer — experiencing every aspect of this vast wilderness. With Nansen’s helicopter capabilities guests can enjoy hours of skiing Greenland’s untracked slopes, her tenders and zodiacs allow for remote landings and remarkably close interactions with wildlife, while continuing to be respectful. Paddle boards and kayaks allow for silent immersion into an landscape punctuated by glaciers and natural floating sculptures of ice and snow.

Reconnecting to nature through wellness — Bazaruto Archipelago, Mozambique
with Kisawa
Immerse into morning sunrise yoga and meditation on the sand dunes of Kisawa Sanctuary — a luxury island property nestled within 300 hectares of pristine coastal beachfront in Mozambique. A team of dedicated chefs will prepare breakfast under canopy, using fresh, organic produce from the Sanctuary’s wild permaculture garden, overlooking the inland Crocodile Lake. VistaJet Members can continue to enjoy a day of specialized wellness rituals, including a Japanese infra-red sauna and Ayurvedic massage at the dedicated Natural Wellness Center. To give thanks to nature, finish the day with beach “glamping” at Ponta Mustita, enjoying an open fire and lantern-lit shoreline.

A desert adventure — Namibia
with Wilderness Safaris
Explore extreme landscapes, accompanied by revered scientist and conservationist Dr Conrad Brain. VistaJet Members will start at the desert retreat, Little Kulala, enjoying nature walks and eco-sensitive quad biking through the famous Sossusvlei Desert, before taking in spectacular views over the sand dunes from a hot air balloon.
Next, guests will venture to Hoanib Skeleton Coast Camp where they will see an unexpected wealth of desert-adapted wildlife, including elephants and giraffes, as well as the Skeleton Coast — a UNESCO World Heritage site where the desert meets the sea, and home to Cape fur seals in their thousands, along with carnivores like the inscrutable brown hyaena. The last stop is Serra Cafema — set under towering trees along the Kunene River, it is one of the most remote camps in southern Africa, and highlights include respectful interaction with neighboring semi-nomadic Himba villagers, boating and guided explorations into the surrounding desert.

Cut your own album — Jamaica
with GUEST
There is a secluded yet delightful corner of a tropical Caribbean island, one with a unique energy and positive vibration that has given rise and nurtured some of the greatest musical artists of our times. VistaJet Members can dial into this musical powerhouse while transforming their creative dreams into the reality of their own album with local or internationally renowned producers and musical artists in support. Staying at Panorama, a contemporary villa set on a half-acre of landscaped gardens, guests enjoy a self-contained haven of modern global living while blending with the natural beauty of the island. A 360-degree view of the mountains, the Caribbean Sea and a surrounding palette of lush vegetation provide idyllic creative conditions with this Jamaican Eden as the ultimate backdrop.

VistaJet’s Private World continues to expand with more partners to more destinations around the world. For additional private travel inspiration, visit vistajet.com/privateworld.

– Ends –

Information
Jennifer Farquhar | VistaJet | press@vistajet.com

About VistaJet
VistaJet is the first and only global business aviation company. On its fleet of over 80 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

For informational purposes only. All bookings are subject to terms and conditions. All travel is subject to applicable rules and regulations, including permits and permissions. VistaJet makes no representations or warrants regarding either the safety or feasibility of any offering.

Attachments

• VistaJet’s Global 7500
• VistaJet’s Private World
• VistaJet’s Private World
• VistaJet’s Private World
• VistaJet’s Private World

December 14, 2021

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips’ portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease. The transaction, which is subject to customary closing conditions, is expected to be completed in the first quarter of 2022. Financial details of the transaction were not disclosed.

Philips already has a leading peripheral vascular portfolio, consisting of: live 2D/3D interventional imaging combined with intravascular ultrasound (IVUS) catheters to provide the visualization and guidance essential for the optimal diagnosis and treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, including the Stellarex drug-coated balloon to treat lesions, and the Tack implantable dissection repair device that restores blood flow in small limb vessels, which Philips added to its offering through the acquisition of Intact Vascular in 2020. With this portfolio, Philips provides clinicians with a complete procedural solution for the treatment of peripheral artery disease (PAD).

Complementing Philips’ strong IVUS offering in venous imaging, Vesper Medical will add a venous stenting solution to address the root cause of chronic deep venous disease (DVD). The Vesper DUO Venous Stent System® consists of venous stents intended to treat deep venous obstruction. Uniquely engineered to address the multiple anatomical challenges of the deep venous system, it provides physicians with a modular portfolio to customize therapy, restore venous flow, and resolve the painful symptoms of deep venous disease for the broad range of patients suffering from chronic venous insufficiency.

“The acquisition of Vesper Medical is another step in our objective to innovate patient treatment with more sophisticated technology and expand our growth in the vascular therapy space,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “Leveraging our significant procedural expertise, we see strong clinical synergies between Vesper Medical’s innovative stenting solution and our existing peripheral vascular offering. This combined offering will help to better support clinicians to decide, guide, treat and confirm during the procedure, thereby enhancing patient care.”

“I am proud that Philips will become the home for our innovations and our people, joining forces to shape the future of treating deep venous disease,” said Bruce Shook, President and CEO of Vesper Medical. “I look forward to further advance our next generation venous technology and bring it to patients and clinicians globally, together with Philips.”

Vesper Medical was founded in 2016 and is headquartered in Wayne, Pennsylvania, US. Upon completion of the transaction, Vesper Medical and approximately 20 of its employees will become part of Philips’ Image-Guided Therapy business.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.

Attachments

• Philips intravascular ultrasound (IVUS) imaging
• Vesper DUO Venous Stent System

Qatar Tourism

DOHA, Qatar, Dec. 13, 2021 (GLOBE NEWSWIRE) — Ground has broken on an exciting new project to bring the world-famous Winter Wonderland to Qatar for five consecutive years, starting November 2022.

Housed on the Al Maha Island near Lusail City just north of Qatar’s capital, Doha Winter Wonderland is a 200,000 square metre venue that will open prior to the FIFA World Cup Qatar 2022™ next November, providing visitors a festive experience during their stay.

Unlike its sister Hyde Park installation in London, which is famous for its variety of festive attractions, activities and entertainment, visitors to Doha Winter Wonderland will find seafront chalets, restaurants, games, and cafes, all under delightful average temperatures in the mid-20°Cs.

Under the patronage and presence of His Excellency Sheikh Khalid bin Khalifa bin Abdulaziz Al Thali, Prime Minister and Minister of Interior, Qatari Diar Company and Qatar Tourism have penned a five-year deal with Elegancia Group to build and operate the project.

Chairman of Qatar Tourism and Qatar Airways Group Chief Executive, His Excellency Mr. Akbar Al Baker, said: “This project, which will be a quality addition to Qatari tourism, is not just a games area, but rather an integrated entertainment destination on par with the foremost entertainment cities in the world.”

Doha Winter Wonderland will include six play areas with more than 50 world-class games for all ages. It will be operated by IMG (International Marketing Group), the same company that manages the event in Hyde Park.

A ground-breaking ceremony on the Al Maha Island was attended by HE Mr. Ali bin Ahmed al-Kuwari, Minister of Finance, HE Sheikh Mohammed bin Hamad bin Qassim al-Thani, Minister of Commerce and Industry, and HE Mr. Jassim bin Saif al-Sulaiti, Minister of Transport. It was also attended by HE Sheikh Khalid bin Khalifa bin Jassim Al Thani, Chairman of the Board of Directors of Qatari Diar, HE Akbar Al Baker, President of Qatar Tourism, HE Eng. Abdullah bin Hamad Al Attiyah, CEO of Qatari Diar, along with many dignitaries.

His Excellency Sheikh Khalid bin Khalifa bin Jassim Al Thani, Chairman of Qatari Diar’s Board of Directors, said: “Once the project is complete, it will not just be a tourist attraction targeting Qatari residents, but one that will go beyond to become a remarkable and distinctive addition to a growing list of world-class tourist destinations in Qatar.”

Eng. Abdullah bin Hamad Al-Attiyah said: “As Lusail City is planned to be a future city that embraces societal diversity, advanced infrastructure, integrated services both public and private, and large local and international institutions and entities, a new world-class entertainment destination such as Doha Winter Wonderland will add a new competitive advantage to the city and will serve as an outlet for residents and visitors.”

Moataz Al Khayat, Chairman of Elegancia Group, said: “We are fortunate to be part of this prestigious project that presents Doha Winter Wonderland as an important milestone in Qatar’s growing and developing tourism sector.”

Further holiday information on Qatar can be found at www.visitqatar.qa.

-Ends-

For media-related inquiries, please contact Qatar Tourism’s Press Office at:

+974 7774 7863 | pressoffice@visitqatar.qa

About Qatar:

Qatar is a peninsula surrounded by the Arabian Gulf in the heart of the Middle East, with 80% of the earth’s population within a six-hour flight. Ranked the safest country in the world in 2020 by Numbeo, Qatar welcomes all travellers, and guests from over 85 countries can enter visa-free. Qatar has an incredible variety of easily accessible tourist attractions, a plethora of fauna and flora including Whale Sharks and the majestic national animal the Arabian Oryx, and most experiences are a unique combination of cultural authenticity and modernity. From iconic museums to high-rise restaurants, from thrilling desert adventures to world-famous events including none other than the FIFA World Cup Qatar 2022™, there is something for all types of travellers and budgets.

About Qatar Tourism:

Qatar Tourism is the official government body responsible for the development and promotion of tourism in Qatar, facilitating the sector’s exponential growth. Qatar is a destination where people of the world come together to experience unique offerings in arts, culture, sports, and adventure, catering to family and business visitors, rooted in Service Excellence. Qatar Tourism seeks to boost the entire tourism value chain, grow local and international visitor demand, attract inward investment, and drive a multiplier effect across the domestic economy. The Qatar Tourism Strategy 2030 sets an ambitious target to attract over six million international visitors a year by 2030, making Qatar the fastest-growing destination in the Middle East.

Web: www.visitqatar.qa

Twitter: @VisitQatar

Instagram: @VisitQatar

Related Images

Image 1: Qatar Tourism

Image 2: Qatar Tourism

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Qatar Tourism

SYDNEY, Dec. 13, 2021 (GLOBE NEWSWIRE) — NEP Australia, a Broadcast Company of NEP Group, the leading media technology partner of content producers worldwide, announced the launch of its second-generation Andrews Hub, capable of supporting all-4K HDR broadcasts through the largest set of facilities worldwide built for Tier 1 live sports coverage.

First opened in 2017, the Andrews Hub is part of NEP’s growing network of centralised production centres and a global production ecosystem. With its main facilities located in Sydney and Melbourne, and satellite locations, or “spokes”, in Adelaide and Brisbane, the Andrews Hub has supported numerous clients in producing shows across continents, often thousands of kilometers away from where the match or live event is taking place – even across the Pacific Ocean.

Demand for remote production began well before COVID-19 when broadcasters realized the benefits of a more efficient and environmentally sustainable approach in which technical producers and directors, replay operators, graphics teams, and on-air talent could all be in different places from where the action was captured. The pandemic accelerated this adoption of centralised and remote workflows as border closures and domestic and international travel restrictions began to severely limit the ability to move crew and talent from one venue to another.

“In 2017 when we launched the Andrews Hub we went to the moon and back in every centralised IP broadcast each day,” said Soames Treffry, President of NEP Australia, New Zealand & Japan. “Our second-generation Andrews Hub is a story of continued investment and innovation in how we’ve built the largest-scale, 4K, centralised production complex on the planet.

“Tier 1 sports broadcasting is in our DNA, and it has driven the development of our own control system, ‘TFC’, and our ‘anyone, anywhere’ philosophy,” he continued. “And with the launch of the Hybrid Grip trailer, we’ll be reducing our onsite footprint even further, making our services more sustainable again.

“Our team are proud to deliver this broadcast leadership to the world.”

Foxtel Group Chief Technology and Operations Officer Les Wigan said: “As Australia’s largest producer of Tier 1 sports, NEP’s commitment to innovation and best-in-class solutions makes them a great long-term partner for our business. Their continued investment supports Fox Sports providing our 2.4 million sports subscribers an outstanding viewing experience across Foxtel and Kayo Sports.”

State-of-the-Art, Sustainable Design, and Innovative Technology Create Room to Grow

As part of its expansion, NEP will build four new control rooms and upgrade its Network Operations Centers to meet increased demand. Work areas for shading and HDR grading of footage before it goes on air will be added, as well as new “mini” studios and commentary suites for on-screen, off-tube commentary.

Other advancements include:

• Expanded state-of-the-art facilities using 100% IP, scalable technology, designed to have the lowest possible impact on the environment.

• The introduction of the “hybrid grip,” a new, all-in-one-style tender/grip trailer with on-board streaming technology built in and ready to hit the road. The single trailer design will include all automated workflows that have made the Andrews Hub so successful, but in a much smaller footprint. As a single trailer only, travel and logistics to move equipment across such a large country becomes more efficient and minimizes the carbon footprint for each project.

• NEP will also deploy a new fully integrated and powerful enterprise resource planning (ERP) package to its broadcast control and orchestration platform, making planning and scheduling more efficient and seamless, and enabling more efficient utilisation of equipment across country borders or in different regions.

“We’ve seen a huge increase in the number of projects we’ve covered through the Andrews Hub due to COVID,” said Marc Segar, NEP’s VP of Enterprise Architecture. “While we were able to add temporary control rooms and remote location ‘spokes’ in Brisbane and Adelaide to get us to where we are today, building the next-generation Andrews Hub facilities in Sydney and Melbourne will further enable us to meet just about any production challenge or configuration for our clients.

“It’s incredible how far we’ve come over the last four years and the future is very bright for live broadcast and centralised production. Fans want to watch sport perhaps more now than before the pandemic, and we are so proud to be a part of delivering that experience to them.”

Learn more about NEP Australia and the Andrews Hub at www.nepgroup.com.au.

About NEP

NEP Group is the leading technology partner for content creators around the globe. For more than 35 years, we have been delivering innovative products and services that enable our clients to make, manage and show the world their content—anywhere, anytime, on any platform. As a trusted partner working on some of the largest productions in the world, NEP offers a complete set of end-to-end solutions, from content capture to distribution—including a growing portfolio of transformational cloud-based, software-based and virtualized technologies. Our Live Production solutions range from AV services and live audience enhancements to traditional outside broadcast and cutting-edge centralized and cloud production. NEP’s Virtual Production solutions start at the creative stage and end with exceptional execution across ICVFX, augmented reality, LED stages and more. And, our Media Processing solutions provide the tools and products our clients need to ingest, edit, store, search, manage and distribute their digital assets to rights holders across multiple platforms.

Headquartered in the United States, NEP has operations in 25 countries with over 4,000 employees. Together, we have supported productions in over 100 countries on all seven continents, and we’re still growing. Our clients range from the leaders in sport, music, film and TV, through to major corporate brands, agencies, to new content owners and creators all around the world. Learn how we are helping clients bring their creative visions, content, live sports and entertainment to life at nepgroup.com.

Attachments

• NEP Australia Andrews Hub Control Room In Action
• Inside Look at the Andrews Hub

Susan Matis
NEP Group
+1 412 423-1339
press@nepgroup.co

Junshi Biosciences and Coherus to meet with US FDA to discuss 1L NSCLC BLA supplement submission

SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus standard-of-care chemotherapy as the first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (“NSCLC”). This interim analysis demonstrated a statistically significant improvement in overall survival, crossing the prespecified efficacy boundary, in patients treated with toripalimab plus chemotherapy. This treatment effect was observed notwithstanding the effects of active crossover to toripalimab at disease progression for patients in the control (placebo plus chemotherapy) arm. As previously reported at the 2021 World Conference on Lung Cancer (WCLC), the study also met the primary endpoint of progression free survival (PFS) per RECIST v1.1 for the toripalimab arm as compared to chemotherapy alone.

Junshi Biosciences and Coherus plan to submit the CHOICE-01 results for publication and request a meeting with the United States Food and Drug Administration (“FDA”) to discuss the submission of a Biologics License Application (“BLA”) supplement for toripalimab in combination with chemotherapy for the first-line treatment of advanced NSCLC. The BLA for toripalimab in combination with gemcitabine and cisplatin for the first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and toripalimab monotherapy for the second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is currently under priority review by the FDA.

“The results of CHOICE-01, demonstrating improvements in overall survival, confirm that toripalimab can deliver significant benefits to patients receiving first-line treatment for non-small cell lung cancer,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “With a consistently strong record of positive efficacy and safety accumulating as data read out from studies across multiple tumor types, we are working to register toripalimab for a broad array of indications in China and the United States. In 2022, we look forward to clinical data from additional Phase 3 studies in NSCLC, small cell lung cancer, triple negative breast cancer, and hepatocellular cancer.”

“The achievement of an overall survival benefit in non-small cell lung cancer patients by toripalimab is a watershed event in the strategic transformation of Coherus and validates the role of toripalimab as the foundation of our immuno-oncology pipeline,” said Denny Lanfear, CEO of Coherus. “Toripalimab has once again delivered positive progression free survival and overall survival clinical data in a first-line setting. We will now work closely with our partners at Junshi Biosciences to engage the FDA on BLA supplement filing strategies for first-line treatment of non-small cell lung cancer. We also look forward to initiating future studies combining toripalimab with a series of complementary immuno-oncology agents to advance patient care and outcomes in oncology.”

About CHOICE-01
A total of 465 treatment-naive advanced NSCLC patients (220 squamous and 245 non-squamous) were randomized (2:1): 309 patients to the toripalimab plus chemotherapy arm and 156 to the placebo plus chemotherapy arm. The primary endpoint was PFS assessed by the investigator. Secondary endpoints included PFS assessed by a blinded independent review committee (BIRC), overall survival (OS), objective response rate (ORR) and duration of response (DoR). Patients in the placebo plus chemotherapy arm were actively crossed-over to toripalimab treatment at disease progression. The addition of toripalimab to standard first-line chemotherapy in patients with advanced NSCLC showed a manageable safety profile with no new safety signals observed.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI^®). Currently, there are 4 approved indications for toripalimab in China:

1. second-line treatment of unresectable or metastatic melanoma;
2. recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy;
3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC.

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the first and second indications (melanoma and NPC).

In addition, two supplemental New Drug Applications (NDAs) for toripalimab were accepted by the National Medical Products Administration (NMPA) for review in China:

• first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
• in combination with chemotherapy as the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR or ALK tumor aberrations.

In the United States, the FDA has granted priority review for the toripalimab BLA for the treatment of recurrent or metastatic NPC, an aggressive head and neck tumor which has no FDA-approved immuno-oncology treatment options. Earlier, the FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for the treatment of esophageal cancer, NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021, Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Junshi Biosciences and Coherus plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.

Coherus markets UDENYCA^® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch toripalimab, an anti-PD-1 antibody, as well as biosimilars of Lucentis^®, Humira^®, and Avastin^®, if approved.

UDENYCA^® is a trademark of Coherus BioSciences, Inc.
Avastin^® and Lucentis^® are registered trademarks of Genentech, Inc.
Humira^® is a registered trademark of AbbVie Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ ability to generate cash flow from its UDENYCA^® business; Coherus’ plans to invest the cash generated by its biosimilar commercial business to build an immuno-oncology franchise; Coherus’ ability to establish a leading position in the immuno-oncology field in the future; Coherus’ and Junshi Biosciences’ ability to co-develop toripalimab for NSCLC or other indications, Coherus’ ability to commercialize toripalimab, or any other drug candidates developed as part of its collaboration with Junshi Biosciences in the licensed territory; the benefits of checkpoint inhibitors; Coherus initiating future studies combining toripalimab with a series of complementary immuno-oncology agents; the results of those future studies; the potential for toripalimab to gain approval in the United States for nasopharyngeal carcinoma, lung cancer, or any indication; registering toripalimab for a broad array of indications in China and the United States; future clinical data from additional Phase 3 studies in NSCLC, small cell lung cancer, triple negative breast cancer, and liver cancer; and Coherus’ ability to prepare for projected launches through 2023 of biosimilars of Humira^®, Avastin^® and Lucentis^®, if approved.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks regarding the current status of the COVID-19 outbreak and the effect it can have on delaying or interrupting key clinical trial activities; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; risks in obtaining sufficient financing for contemplated clinical trials; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; risks related to Coherus’ collaboration with Junshi Biosciences; risks of the drug development position of Coherus’ competitors; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021, its subsequent Quarterly Reports on Form 10-Q, including the sections therein captioned “Risk Factors,” and in other documents we file with the Securities and Exchange Commission.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Coherus Contact Information:

IR Contact:
McDavid Stilwell
Coherus BioSciences, Inc.
mstilwell@coherus.com
+1 (650) 395-0152

Media Contact:
Cheston Turbyfill
cturbyfill@coherus.com